Chimeric Antigen Receptor Dendritic Cell (CAR-DC) for Treatment of Cancer
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 17/559,967, filed Dec 22, 2021. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,517,589 | Chimeric Antigen Receptor Dendritic Cell (CAR-DC) for Treatment of Cancer In force · High confidence | Create Medicines, Inc. | In force | High confidence | ||
| US 11,918,604 | Chimeric Antigen Receptor Dendritic Cell (CAR-DC) for Treatment of Cancer In force · High confidence | Create Medicines, Inc. | In force | High confidence | ||
| US 11,918,605 | Chimeric Antigen Receptor Dendritic Cell (CAR-DC) for Treatment of Cancer In force · High confidence | Create Medicines, Inc. | In force | High confidence | ||
| Application 18/420,382 | Chimeric Antigen Receptor Dendritic Cell (CAR-DC) for Treatment of Cancer Pending Not granted | Create Medicines, Inc. | Pending | Not granted |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Create Medicines, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.